These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. Endzeliņš E; Melne V; Kalniņa Z; Lietuvietis V; Riekstiņa U; Llorente A; Linē A Mol Cancer; 2016 May; 15(1):41. PubMed ID: 27189160 [TBL] [Abstract][Full Text] [Related]
3. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. Endzeliņš E; Berger A; Melne V; Bajo-Santos C; Soboļevska K; Ābols A; Rodriguez M; Šantare D; Rudņickiha A; Lietuvietis V; Llorente A; Linē A BMC Cancer; 2017 Nov; 17(1):730. PubMed ID: 29121858 [TBL] [Abstract][Full Text] [Related]
4. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer. Aboutalebi H; Bahrami A; Soleimani A; Saeedi N; Rahmani F; Khazaei M; Fiuji H; Shafiee M; Ferns GA; Avan A; Hassanian SM Int J Biochem Cell Biol; 2020 Jul; 124():105765. PubMed ID: 32428568 [TBL] [Abstract][Full Text] [Related]
5. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma. Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743 [TBL] [Abstract][Full Text] [Related]
6. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071 [TBL] [Abstract][Full Text] [Related]
7. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Kosaka N; Iguchi H; Ochiya T Cancer Sci; 2010 Oct; 101(10):2087-92. PubMed ID: 20624164 [TBL] [Abstract][Full Text] [Related]
8. Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection. Cirillo PDR; Margiotti K; Fabiani M; Barros-Filho MC; Sparacino D; Cima A; Longo SA; Cupellaro M; Mesoraca A; Giorlandino C PLoS One; 2021; 16(8):e0255804. PubMed ID: 34352040 [TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review. Huang YK; Yu JC World J Gastroenterol; 2015 Sep; 21(34):9863-86. PubMed ID: 26379393 [TBL] [Abstract][Full Text] [Related]
10. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer. Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713 [TBL] [Abstract][Full Text] [Related]
11. The clinical impact of intra- and extracellular miRNAs in ovarian cancer. Yoshida K; Yokoi A; Kato T; Ochiya T; Yamamoto Y Cancer Sci; 2020 Oct; 111(10):3435-3444. PubMed ID: 32750177 [TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Schwarzenbach H Expert Rev Mol Diagn; 2015; 15(9):1159-69. PubMed ID: 26202667 [TBL] [Abstract][Full Text] [Related]
13. Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. Chakraborty C; Das S Tumour Biol; 2016 May; 37(5):5705-14. PubMed ID: 26831657 [TBL] [Abstract][Full Text] [Related]
14. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048 [TBL] [Abstract][Full Text] [Related]